ALKS

SEC source: 0001127602-25-004948 · form4.xml · derivative · entry 11

Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Ordinary Shares · 108,833 shares

Expires 2029-02-21

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This option exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 12/14/2023.

F7 · derivative.exercise_date: These options are fully vested in accordance with their terms.

SEC source: 0001127602-25-004948 · form4.xml · nonDerivative · entry 8

Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 57,875

F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 12/14/2023.

F6 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $36.00 to $36.05. Full information regarding the number of shares sold at each separate price can be provided to the issuer, any security holder of the issuer or the SEC staff upon request.

SEC source: 0001127602-25-004948 · form4.xml · nonDerivative · entry 7

Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 166,708

F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 12/14/2023.

F5 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $34.00 to $34.07. Full information regarding the number of shares sold at each separate price can be provided to the issuer, any security holder of the issuer or the SEC staff upon request.

SEC source: 0001127602-25-004948 · form4.xml · nonDerivative · entry 6

Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 202,294

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This option exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 12/14/2023.

SEC source: 0001127602-25-004948 · form4.xml · nonDerivative · entry 5

Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 166,708

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This option exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 12/14/2023.

SEC source: 0001127602-25-004948 · form4.xml · derivative · entry 10

Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 50,104

Underlying: Ordinary Shares · 111,630 shares

Expires 2031-02-22

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This option exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 12/14/2023.

F8 · derivative.exercise_date: Shares underlying the stock option vest and become exercisable in four equal annual installments commencing on 2/22/2022.

SEC source: 0001127602-25-004948 · form4.xml · derivative · entry 9

Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Ordinary Shares · 87,566 shares

Expires 2030-02-20

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This option exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 12/14/2023.

F7 · derivative.exercise_date: These options are fully vested in accordance with their terms.

SEC source: 0001127602-25-004948 · form4.xml · nonDerivative · entry 4

Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 57,875

F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 12/14/2023.

F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $33.00 to $33.52. Full information regarding the number of shares sold at each separate price can be provided to the issuer, any security holder of the issuer or the SEC staff upon request.

SEC source: 0001127602-25-004948 · form4.xml · nonDerivative · entry 3

Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 90,983

F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 12/14/2023.

F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $32.00 to $32.9998. Full information regarding the number of shares sold at each separate price can be provided to the issuer, any security holder of the issuer or the SEC staff upon request.

SEC source: 0001127602-25-004948 · form4.xml · nonDerivative · entry 2

Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 262,796

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This option exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 12/14/2023.

SEC source: 0001127602-25-004948 · form4.xml · nonDerivative · entry 1

Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 151,166

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This option exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 12/14/2023.

SEC source: 0001127602-25-003685 · form4.xml · nonDerivative · entry 2

POPS RICHARD F · CIK 0001126490 · Director · Director and CEO, Alkermes plc

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,290,390

SEC source: 0001127602-25-003685 · form4.xml · nonDerivative · entry 1

POPS RICHARD F · CIK 0001126490 · Director · Director and CEO, Alkermes plc

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,370,315

F1 · price: These ordinary shares were acquired by the reporting person as a result of the vesting of performance-vesting restricted stock unit awards granted to the reporting person on February 18, 2022 with a three-year performance period that ended on December 31, 2024 (the "2022 PRSUs"). The vesting of this portion of the 2022 PRSUs was triggered by the determination of achievement of certain pre-specified performance goals and application of a total shareholder return modifier and represents the final vesting event under the 2022 PRSUs.

SEC source: 0001127602-25-003684 · form4.xml · nonDerivative · entry 2

Nichols Christian Todd · CIK 0001813312 · SVP, Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 77,869

SEC source: 0001127602-25-003684 · form4.xml · nonDerivative · entry 1

Nichols Christian Todd · CIK 0001813312 · SVP, Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 85,268

F1 · price: These ordinary shares were acquired by the reporting person as a result of the vesting of performance-vesting restricted stock unit awards granted to the reporting person on February 18, 2022 with a three-year performance period that ended on December 31, 2024 (the "2022 PRSUs"). The vesting of this portion of the 2022 PRSUs was triggered by the determination of achievement of certain pre-specified performance goals and application of a total shareholder return modifier and represents the final vesting event under the 2022 PRSUs.

SEC source: 0001127602-25-003680 · form4.xml · nonDerivative · entry 2

Jackson Blair Curtis · CIK 0001842348 · EVP, Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 181,548

SEC source: 0001127602-25-003680 · form4.xml · nonDerivative · entry 1

Jackson Blair Curtis · CIK 0001842348 · EVP, Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 192,195

F1 · price: These ordinary shares were acquired by the reporting person as a result of the vesting of performance-vesting restricted stock unit awards granted to the reporting person on February 18, 2022 with a three-year performance period that ended on December 31, 2024 (the "2022 PRSUs"). The vesting of this portion of the 2022 PRSUs was triggered by the determination of achievement of certain pre-specified performance goals and application of a total shareholder return modifier and represents the final vesting event under the 2022 PRSUs.

SEC source: 0001127602-25-003679 · form4.xml · nonDerivative · entry 2

Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 63,600

SEC source: 0001127602-25-003679 · form4.xml · nonDerivative · entry 1

Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 78,683

F1 · price: These ordinary shares were acquired by the reporting person as a result of the vesting of performance-vesting restricted stock unit awards granted to the reporting person on February 18, 2022 with a three-year performance period that ended on December 31, 2024 (the "2022 PRSUs"). The vesting of this portion of the 2022 PRSUs was triggered by the determination of achievement of certain pre-specified performance goals and application of a total shareholder return modifier and represents the final vesting event under the 2022 PRSUs.

SEC source: 0001127602-25-003678 · form4.xml · nonDerivative · entry 2

Gaffin David Joseph · CIK 0001675905 · EVP, CLO, Alkermes, Inc.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 188,499

SEC source: 0001127602-25-003678 · form4.xml · nonDerivative · entry 1

Gaffin David Joseph · CIK 0001675905 · EVP, CLO, Alkermes, Inc.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 198,251

F1 · price: These ordinary shares were acquired by the reporting person as a result of the vesting of performance-vesting restricted stock unit awards granted to the reporting person on February 18, 2022 and August 3, 2022 with a three-year performance period that ended on December 31, 2024 (the "2022 PRSUs"). The vesting of this portion of the 2022 PRSUs was triggered by the determination of achievement of certain pre-specified performance goals and application of a total shareholder return modifier and represents the final vesting event under the 2022 PRSUs.

SEC source: 0001127602-25-003677 · form4.xml · nonDerivative · entry 2

Brown Iain Michael · CIK 0001643456 · SVP, Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 133,395

SEC source: 0001127602-25-003677 · form4.xml · nonDerivative · entry 1

Brown Iain Michael · CIK 0001643456 · SVP, Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 140,909

F1 · price: These ordinary shares were acquired by the reporting person as a result of the vesting of performance-vesting restricted stock unit awards granted to the reporting person on February 18, 2022 with a three-year performance period that ended on December 31, 2024 (the "2022 PRSUs"). The vesting of this portion of the 2022 PRSUs was triggered by the determination of achievement of certain pre-specified performance goals and application of a total shareholder return modifier and represents the final vesting event under the 2022 PRSUs.

SEC source: 0001127602-25-002645 · form4.xml · derivative · entry 9

Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 92,271

Underlying: Ordinary Shares · 18,345 shares

Expires 2033-02-23

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This option exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 12/14/2023.

F7 · derivative.exercise_date: Shares underlying the stock option vest and become exercisable in four equal annual installments commencing on 2/23/2024.

SEC source: 0001127602-25-002645 · form4.xml · derivative · entry 8

Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 106,758

Underlying: Ordinary Shares · 23,542 shares

Expires 2032-02-18

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This option exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 12/14/2023.

F6 · derivative.exercise_date: Shares underlying the stock option vest and become exercisable in four equal annual installments commencing on 2/18/2023.

SEC source: 0001127602-25-002645 · form4.xml · derivative · entry 7

Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 161,734

Underlying: Ordinary Shares · 26,589 shares

Expires 2031-02-22

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This option exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 12/14/2023.

F5 · derivative.exercise_date: Shares underlying the stock option vest and become exercisable in four equal annual installments commencing on 2/22/2022.

SEC source: 0001127602-25-002645 · form4.xml · derivative · entry 6

Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 87,566

Underlying: Ordinary Shares · 29,156 shares

Expires 2030-02-20

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This option exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 12/14/2023.

F4 · derivative.exercise_date: These options are fully vested in accordance with their terms.

SEC source: 0001127602-25-002645 · form4.xml · nonDerivative · entry 5

Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 44,290

F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 12/14/2023.

F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $32.00 to $32.17. Full information regarding the number of shares sold at each separate price can be provided to the issuer, any security holder of the issuer or the SEC staff upon request.

SEC source: 0001127602-25-002645 · form4.xml · nonDerivative · entry 4

Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 145,208

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This option exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 12/14/2023.

SEC source: 0001127602-25-002645 · form4.xml · nonDerivative · entry 3

Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 126,863

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This option exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 12/14/2023.

SEC source: 0001127602-25-002645 · form4.xml · nonDerivative · entry 2

Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 103,321

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This option exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 12/14/2023.

SEC source: 0001127602-25-002645 · form4.xml · nonDerivative · entry 1

Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 76,732

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This option exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 12/14/2023.

SEC source: 0001127602-24-028884 · form4.xml · derivative · entry 6

LAURENCIN CATO T · CIK 0001444810 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 16,142

Underlying: Ordinary Shares · 2,691 shares

Expires 2031-12-08

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · kind: This option exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 2/26/2023.

F5 · derivative.exercise_date: These options are fully vested in accordance with their terms.

SEC source: 0001127602-24-028884 · form4.xml · nonDerivative · entry 4

LAURENCIN CATO T · CIK 0001444810 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 23,013

F3 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 2/26/2023.

SEC source: 0001127602-24-028884 · form4.xml · nonDerivative · entry 3

LAURENCIN CATO T · CIK 0001444810 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 25,704

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · kind: This option exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 2/26/2023.

SEC source: 0001127602-24-028885 · form4.xml · derivative · entry 9

Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 110,616

Underlying: Ordinary Shares · 12,411 shares

Expires 2033-02-23

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This option exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 12/14/2023.

F7 · derivative.exercise_date: Shares underlying the stock option vest and become exercisable in four equal annual installments commencing on 2/23/2024.

SEC source: 0001127602-24-028885 · form4.xml · derivative · entry 8

Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 130,300

Underlying: Ordinary Shares · 12,044 shares

Expires 2032-02-18

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This option exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 12/14/2023.

F6 · derivative.exercise_date: Shares underlying the stock option vest and become exercisable in four equal annual installments commencing on 2/18/2023.

SEC source: 0001127602-24-028885 · form4.xml · derivative · entry 7

Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 188,323

Underlying: Ordinary Shares · 12,090 shares

Expires 2031-02-22

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This option exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 12/14/2023.

F5 · derivative.exercise_date: Shares underlying the stock option vest and become exercisable in four equal annual installments commencing on 2/22/2022.

SEC source: 0001127602-24-028885 · form4.xml · derivative · entry 6

Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 116,722

Underlying: Ordinary Shares · 12,452 shares

Expires 2030-02-20

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This option exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 12/14/2023.

F4 · derivative.exercise_date: These options are fully vested in accordance with their terms.

SEC source: 0001127602-24-028885 · form4.xml · nonDerivative · entry 5

Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 47,576

F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 12/14/2023.

F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $32.00 to $32.2514. Full information regarding the number of shares sold at each separate price can be provided to the issuer, any security holder of the issuer or the SEC staff upon request.

SEC source: 0001127602-24-028885 · form4.xml · nonDerivative · entry 4

Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 108,727

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This option exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 12/14/2023.

SEC source: 0001127602-24-028885 · form4.xml · nonDerivative · entry 3

Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 96,316

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This option exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 12/14/2023.

SEC source: 0001127602-24-028885 · form4.xml · nonDerivative · entry 2

Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 84,272

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This option exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 12/14/2023.

SEC source: 0001127602-24-028885 · form4.xml · nonDerivative · entry 1

Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 72,182

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This option exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 12/14/2023.

SEC source: 0001127602-24-028884 · form4.xml · derivative · entry 5

LAURENCIN CATO T · CIK 0001444810 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Ordinary Shares · 4,163 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share.

F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share.

F4 · derivative.exercise_date: This award is fully vested in accordance with its terms.

F4 · derivative.expiration_date: This award is fully vested in accordance with its terms.

SEC source: 0001127602-24-028884 · form4.xml · nonDerivative · entry 2

LAURENCIN CATO T · CIK 0001444810 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 23,013

SEC source: 0001127602-24-028884 · form4.xml · nonDerivative · entry 1

LAURENCIN CATO T · CIK 0001444810 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 23,971

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share.

SEC source: 0001127602-24-028740 · form4.xml · nonDerivative · entry 1

Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 59,730

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 12/14/2023.

SEC source: 0001127602-24-028647 · form4.xml · nonDerivative · entry 1

Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 68,951

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 12/14/2023.

F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $30.50 to $31.00. Full information regarding the number of shares sold at each separate price can be provided to the issuer, any security holder of the issuer or the SEC staff upon request.

SEC source: 0001127602-24-028173 · form4.xml · nonDerivative · entry 1

Nichols Christian Todd · CIK 0001813312 · SVP, Chief Commercial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 60,703

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 8/23/2024.